P651 Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience
Harland S. Winter(Massachusetts General Hospital), Jeffrey S. Hyams(Connecticut Children's Medical Center), Y Wang(Janssen (United States)), Christopher Busse(Janssen (United States)), James Izanec(Janssen (United States))
Cited by 0
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k